Effects of orally active hypoxia inducible factor alpha prolyl hydroxylase inhibitor, FG4592 on renal fibrogenic potential in mouse unilateral ureteral obstruction model

• Main Authors: Kazuya Kabei (Author), Yu Tateishi (Author), Masayuki Shiota (Author), Mayuko Osada-Oka (Author), Shunji Nishide (Author), Junji Uchida (Author), Tatsuya Nakatani (Author), Shinji Matsunaga (Author), Takehiro Yamaguchi (Author), Shuhei Tomita (Author), Katsuyuki Miura (Author)
• Format: Book
• Published: Elsevier, 2020-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Orally active hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors that stabilize HIF protein and stimulate the production of erythropoietin have been approved to treat renal anemia. Our previous report suggested that HIF-1α dependent fibrogenic mechanisms are operating at the early onset of...